Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

A novel proteomic biomarker panel as a diagnostic tool for patients with ovarian cancer

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Preserved postprandial suppression of bone turnover markers, despite increased fasting levels, in postmenopausal women

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. DIAGNOSIS OF ENDOCRINE DISEASE: Sex steroid action in adolescence: too much, too little; too early, too late

    Research output: Contribution to journalReviewResearchpeer-review

  3. Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Intrafractional fiducial marker position variations in stereotactic liver radiotherapy during voluntary deep inspiration breath-hold

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Prognostic utility of serum YKL-40 in patients with cervical cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
Previous reports have shown that the proteomic markers apolipoprotein A1, hepcidin, transferrin, inter-alpha trypsin IV internal fragment, transthyretin, connective-tissue activating protein 3 and beta-2 microglobulin may discriminate between a benign pelvic mass and ovarian cancer (OC). The aim was to determine if these serum proteomic biomarkers alone as well as in combination with age and serum CA125, could be helpful in triage of women with a pelvic mass.
Original languageEnglish
JournalGynecologic Oncology
Volume123
Issue number2
Pages (from-to)308-13
Number of pages6
ISSN0090-8258
DOIs
Publication statusPublished - 2011

    Research areas

  • Adult, Aged, Aged, 80 and over, CA-125 Antigen, Female, Humans, Logistic Models, Middle Aged, Neoplasm Proteins, Odds Ratio, Ovarian Neoplasms, Proteomics, Sensitivity and Specificity, Tumor Markers, Biological

ID: 33230114